Literature DB >> 29530506

Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists.

Martyna Szpakowska1, Max Meyrath2, Nathan Reynders3, Manuel Counson2, Julien Hanson4, Jan Steyaert5, Andy Chevigné6.   

Abstract

The atypical chemokine receptor ACKR3/CXCR7 plays crucial roles in numerous physiological processes but also in viral infection and cancer. ACKR3 shows strong propensity for activation and, unlike classical chemokine receptors, can respond to chemokines from both the CXC and CC families as well as to the endogenous peptides BAM22 and adrenomedullin. Moreover, despite belonging to the G protein coupled receptor family, its function appears to be mainly dependent on β-arrestin. ACKR3 has also been shown to continuously cycle between the plasma membrane and the endosomal compartments, suggesting a possible role as a scavenging receptor. So far, the molecular basis accounting for these atypical binding and signalling properties remains elusive. Noteworthy, ACKR3 extracellular domains bear three disulphide bridges. Two of them lie on top of the two main binding subpockets and are conserved among chemokine receptors, and one, specific to ACKR3, forms an intra-N terminus four-residue-loop of so far unknown function. Here, by mutational and functional studies, we examined the impact of the different disulphide bridges for ACKR3 folding, ligand binding and activation. We showed that, in contrast to most classical chemokine receptors, none of the extracellular disulphide bridges was essential for ACKR3 function. However, the disruption of the unique ACKR3 N-terminal loop drastically reduced the binding of CC chemokines whereas it only had a mild impact on CXC chemokine binding. Mutagenesis also uncovered that chemokine and endogenous non-chemokine ligands interact and activate ACKR3 according to distinct binding modes characterized by different transmembrane domain subpocket occupancy and N-terminal loop contribution, with BAM22 mimicking the binding mode of CC chemokine N terminus.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACKR3; Adrenomedullin; BAM22; CXCL12; CXCR4; CXCR7; Chemokine receptor

Mesh:

Substances:

Year:  2018        PMID: 29530506     DOI: 10.1016/j.bcp.2018.03.007

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  13 in total

Review 1.  Stromal cell-derived factor-1 (CXCL12) and its role in bone and muscle biology.

Authors:  William Gilbert; Robert Bragg; Ahmed M Elmansi; Meghan E McGee-Lawrence; Carlos M Isales; Mark W Hamrick; William D Hill; Sadanand Fulzele
Journal:  Cytokine       Date:  2019-07-20       Impact factor: 3.861

Review 2.  Emerging Roles of the Atypical Chemokine Receptor 3 (ACKR3) in Cardiovascular Diseases.

Authors:  Vincent Duval; Paul Alayrac; Jean-Sébastien Silvestre; Angélique Levoye
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-29       Impact factor: 6.055

3.  Structural Features of an Extended C-Terminal Tail Modulate the Function of the Chemokine CCL21.

Authors:  Natasha A Moussouras; Gertrud M Hjortø; Francis C Peterson; Martyna Szpakowska; Andy Chevigné; Mette M Rosenkilde; Brian F Volkman; Michael B Dwinell
Journal:  Biochemistry       Date:  2020-03-26       Impact factor: 3.162

4.  The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides.

Authors:  Max Meyrath; Martyna Szpakowska; Julian Zeiner; Laurent Massotte; Myriam P Merz; Tobias Benkel; Katharina Simon; Jochen Ohnmacht; Jonathan D Turner; Rejko Krüger; Vincent Seutin; Markus Ollert; Evi Kostenis; Andy Chevigné
Journal:  Nat Commun       Date:  2020-06-19       Impact factor: 14.919

5.  Predominance of the heterozygous CCR5 delta-24 deletion in African individuals resistant to HIV infection might be related to a defect in CCR5 addressing at the cell surface.

Authors:  Vic Arendt; Mathieu Amand; Gilles Iserentant; Morgane Lemaire; Cécile Masquelier; Gilles F Ndayisaba; Chris Verhofstede; Etienne Karita; Susan Allen; Andy Chevigné; Jean-Claude Schmit; Danielle Perez Bercoff; Carole Seguin-Devaux
Journal:  J Int AIDS Soc       Date:  2019-09       Impact factor: 5.396

Review 6.  The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment.

Authors:  Nathan Reynders; Dayana Abboud; Alessandra Baragli; Muhammad Zaeem Noman; Bernard Rogister; Simone P Niclou; Nikolaus Heveker; Bassam Janji; Julien Hanson; Martyna Szpakowska; Andy Chevigné
Journal:  Cells       Date:  2019-06-18       Impact factor: 6.600

7.  The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma.

Authors:  Virginie Neirinckx; Ann-Christin Hau; Anne Schuster; Sabrina Fritah; Katja Tiemann; Eliane Klein; Petr V Nazarov; André Matagne; Martyna Szpakowska; Max Meyrath; Andy Chevigné; Mirko H H Schmidt; Simone P Niclou
Journal:  Neurooncol Adv       Date:  2019-09-06

8.  CXCR4 and CXCR3 are two distinct prognostic biomarkers in breast cancer: Database mining for CXCR family members.

Authors:  Kaibo Guo; Guan Feng; Qingying Yan; Leitao Sun; Kai Zhang; Fengfei Shen; Minhe Shen; Shanming Ruan
Journal:  Mol Med Rep       Date:  2019-10-30       Impact factor: 2.952

9.  Lymphatic endothelial-cell expressed ACKR3 is dispensable for postnatal lymphangiogenesis and lymphatic drainage function in mice.

Authors:  Elena C Sigmund; Lilian Baur; Philipp Schineis; Jorge Arasa; Victor Collado-Diaz; Martina Vranova; Rolf A K Stahl; Marcus Thelen; Cornelia Halin
Journal:  PLoS One       Date:  2021-04-15       Impact factor: 3.240

10.  CXCL14 Preferentially Synergizes With Homeostatic Chemokine Receptor Systems.

Authors:  Ariadni Kouzeli; Paul J Collins; Mieke Metzemaekers; Max Meyrath; Martyna Szpakowska; Marc Artinger; Sofie Struyf; Paul Proost; Andy Chevigne; Daniel F Legler; Matthias Eberl; Bernhard Moser
Journal:  Front Immunol       Date:  2020-10-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.